Cavazzoni Appeals For Pragmatic Approach To Clinic Trial Diversity Plans

In another attempt to address concerns about the new mandate, the director of the US FDA’s Center for Drug Evaluation and Research said the agency must balance its interest in trial diversity with the need to get treatments to patients as soon as possible.